Literature DB >> 14696020

Comparative study of acute effects of single doses of fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy volunteers.

Hiroyuki Kamei1, Yukihiro Noda, Kazuhiro Ishikawa, Koji Senzaki, Isao Muraoka, Yoshinori Hasegawa, Ian Hindmarch, Toshitaka Nabeshima.   

Abstract

Since most classical (first-generation) antihistamines have undesirable sedative effects on the central nervous system (CNS), newer (second-generation) antihistamines have been developed to relieve the sedative effects and to improve the patient's quality of life. However, the psychomotor profiles of second-generation antihistamines are not fully elucidated. In this randomized, double-blind, crossover study, the acute effects of single doses of second-generation antihistamines, fexofenadine (120 mg) and olopatadine (10 mg), on cognitive and psychomotor performance were investigated in comparison with those of placebo and d-chlorpheniramine (4 mg), a first-generation antihistamine, using objective and subjective assessments, in 11 healthy Japanese volunteers. In a battery of psychomotor tests, d-chlorpheniramine impaired tracking ability in the compensatory tracking task and caused a reduction in behavioural activity as continuously measured by wrist actigraphy. Olopatadine, like d-chlorpheniramine, reduced the behavioural activity, while fexofenadine had no effect in any of the tests. No significant changes in the subjects' self-ratings of drowsiness were found with the three antihistamines. These results suggest that d-chlorpheniramine and olopatadine, but not fexofenadine, produce sedative effects on psychomotor performance, and that the CNS profile of fexofenadine is different from that of olopatadine. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14696020     DOI: 10.1002/hup.538

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  8 in total

1.  Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen.

Authors:  Manabu Tashiro; Hideki Mochizuki; Yumiko Sakurada; Kenji Ishii; Keiichi Oda; Yuichi Kimura; Toru Sasaki; Kiichi Ishiwata; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

2.  Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance.

Authors:  Eef L Theunissen; Annemiek Vermeeren; Johannes G Ramaekers
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 3.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Maintenance of remission with low-dose olopatadine hydrochloride for itch in well-controlled chronic urticaria.

Authors:  Teruhiko Makino; Yoshiaki Takegami; Mati Ur Rehman; Yoko Yoshihisa; Waka Ishida; Takashi Toyomoto; Tadamichi Shimizu
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-09-19

5.  Fexofenadine hydrochloride in the treatment of allergic disease: a review.

Authors:  David Axelrod; Leonard Bielory
Journal:  J Asthma Allergy       Date:  2008-09-19

Review 6.  Central nervous system effects of the second-generation antihistamines marketed in Japan--review of inter-drug differences using the proportional impairment ratio (PIR)-.

Authors:  Tatsuya Isomura; Takeshi Kono; Ian Hindmarch; Norimasa Kikuchi; Aya Murakami; Kyoko Inuzuka; Seiji Kawana
Journal:  PLoS One       Date:  2014-12-12       Impact factor: 3.240

Review 7.  Ocular allergy treatment comparisons: azelastine and olopatadine.

Authors:  Leonard Bielory; Praveen Buddiga; Stephen Bigelson
Journal:  Curr Allergy Asthma Rep       Date:  2004-07       Impact factor: 4.919

8.  Antihistamine effects and safety of fexofenadine: a systematic review and Meta-analysis of randomized controlled trials.

Authors:  Cheng-Zhi Huang; Zhi-Hui Jiang; Jian Wang; Yue Luo; Hua Peng
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-29       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.